Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 3Breast Neoplasms 2Anorexia 2Vomiting 1Neoplasms, Second Primary 1Mesothelioma, Malignant 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Cachexia 1

Interventions

Cisplatin 28Radiotherapy 20pembrolizumab 9Paclitaxel 9Surveys and Questionnaires 8Cetuximab 8Fluorouracil 7Docetaxel 7Radiotherapy, Intensity-Modulated 6Carboplatin 6apatinib 5Low-Level Light Therapy 5Blood Specimen Collection 5durvalumab 4Standard of Care 4Magnetic Resonance Imaging 4Gemcitabine 4Cyclophosphamide 4Celecoxib 4Tegafur 3Radiation 3Oncolytic Virotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lidocaine 3Immunoenzyme Techniques 3Drug Therapy 3Chemotherapy, Adjuvant 3Biopsy 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Head and Neck Neoplasms × Megestrol Acetate × Clear all
NCT02980653 2017-01-18

Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT

TTY Biopharm

Phase 2 Unknown
105 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡